The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Open accessAbstract
Acetyl coenzyme A (AcCoA) is the central biosynthetic precursor for fatty-acid synthesis and protein acetylation. In the conventional view of mammalian cell metabolism, AcCoA is primarily generated from glucose-derived pyruvate through the citrate shuttle and ATP citrate lyase in the cytosol. However, proliferating cells that exhibit aerobic glycolysis and those exposed to hypoxia convert glucose to lactate at near-stoichiometric levels, directing glucose carbon away from the tricarboxylic acid cycle and fatty-acid synthesis. Although glutamine is consumed at levels exceeding that required for nitrogen biosynthesis, the regulation and use of glutamine metabolism in hypoxic cells is not well understood. Here we show that human cells use reductive metabolism of α-ketoglutarate to synthesize AcCoA for lipid synthesis. This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is active in most cell lines under normal culture conditions, but cells grown under hypoxia rely almost exclusively on the reductive carboxylation of glutamine-derived α-ketoglutarate for de novo lipogenesis. Furthermore, renal cell lines deficient in the von Hippel-Lindau tumour suppressor protein preferentially use reductive glutamine metabolism for lipid biosynthesis even at normal oxygen levels. These results identify a critical role for oxygen in regulating carbon use to produce AcCoA and support lipid synthesis in mammalian cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both HIF-1α and HIF-2α activation promotes the upregulation of the glutamine transporter, SLC38A2, which increases the dependency of cells to glutamine and correlates with poorer survival in patients with breast cancer [58]”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of constitutive HIF-2α stabilization75 or a defective mitochondrial electron transport chain76, glutamine-derived α-KG is reductively carboxylated through the consumption of NADPH by IDH2 to generate citrate.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [75]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, checkpoint kinase 1 (CHK1) inhibitors625–627 and glutaminase (GLS) inhibitors628–634 are also considered potential candidates for treating Myc-overexpressing cancers.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [631]
In the citing paper
“Citrate, generated by reductive carboxylation of α-KG, is especially crucial for lipid synthesis under low-oxygen conditions24,25.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [24]
In the citing paper
“and switch the fate of glutamine from the oxidative pathway into the reductive carboxylation pathway24.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [24]
In the citing paper
“Glutamine acts as an alternative fuel for fatty acid synthesis, supplying citrate via mitochondrial reductive carboxylation, especially under hypoxic conditions74,75.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [75]
In the citing paper
“Alternatively, proliferating cells under hypoxia have been reported to predominantly reductively carboxylate glutamine generated α-ketoglutarate through IDH 1/2 to generate M5 citrate (Figure 4A) (Metallo, 2012).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“Previous reports showed that reductive carboxylation is a critical pathway to support the growth of tumor cells under hypoxia (Metallo, 2012; Mullen, 2012).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“The upregulation of the reductive carboxylation pathway enhances cancer cells proliferation (Metallo, 2012; Mullen, 2012; Wise et al., 2011).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“For example, under conditions of hypoxia or impaired mitochondrial respiration, certain reactions of the TCA cycle reverse to support glutamine-dependent reductive carboxylation (92, 122, 123).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [122]
In the citing paper
“In a process referred to as reductive carboxylation, a section of the TCA cycle reverses itself, converting α-ketoglutarate into citrate, which can be then used to generate a source of cytosolic acetyl-CoA (Metallo et al., 2012; Wise et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Metallo et al., 2012
In the citing paper
“Citrate is generated by citrate synthase (CS) or through the reduction of α-ketoglutarate by isocitrate dehydrogenase (IDH).79–81”
From The multifaceted contributions of mitochondria to cellular metabolism (2018) · cites this paper as [79]
In the citing paper
“Citrate levels, however, were markedly decreased in Mpc1KD or Mpc2KD (Mpc1/2KD) cells, as this metabolite is generated predominantly from pyruvate-derived AcCoA under normal growth conditions (Metallo et al., 2012).”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“Glutamine can contribute carbon to fatty acid synthesis via reductive carboxylation or oxidative glutaminolysis.”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“The former pathway is highly active in cells proliferating under hypoxia or those with a compromised respiratory chain (Metallo et al., 2012; Mullen et al., 2012; Scott et al., 2011; Wise et al., 2011), while the latter pathway has been observed in B cell lymphoma (Le et al., 2012).”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“This switch to reductive versus oxidative metabolism of α-KG is regulated in part by HIF-1α (71, 72), although the exact mechanism by which HIF-1α does so remains unclear.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“Although oxidation of glutamine-derived α-KG in the TCA cycle serves as a minor source of lipogenic acetyl-CoA under normal growth conditions, α-KG can be converted to citrate through reductive carboxylation under conditions of stress such as hypoxia or mitochondrial dysfunction (70–72).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“The work from Metallo and colleagues (71) suggests that T cells can use reductive glutamine metabolism for fatty acid biosynthesis under hypoxic conditions.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“In place of oxidative metabolism of both glucose and glutamine, these cancers preferentially perform reductive and carboxylating biosynthetic reactions from glutamine carbon (Le et al., 2012; Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Metallo et al., 2012
In the citing paper
“Recently three independent reports implicated IDH-dependent reductive carboxylation as playing a particularly important role in proliferating cells that exhibit decreased flux of glucose-derived pyruvate into the mitochondria. This occurs in hypoxic cells or in cells harboring defects in mitochondrial oxidative phosphorylation (Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Metallo et al., 2012
In the citing paper
“tumor cells with mutations in the TCA cycle or ETC (Mullen et al., 2011), or with hypoxia-induced suppression of oxidative metabolism (Metallo et al., 2011; Scott et al., 2011; Wise et al., 2011) use reductive carboxylation of α-KG to produce citrate and other precursors during growth.”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Metallo et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The von Hippel–Lindau (VHL) tumour suppressor protein is frequently lost in renal cell carcinoma (RCC) and results in a state of ‘pseudohypoxia’ by activating HIF signallin”
BackgroundKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Cited by
Sorted by citations
Items 601–700 of 1,003
Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer
Zecchini, V. R., Madhu, B., Russell, R., Pértega‐Gomes, N., Warren, A. Y., Gaude, E., Borlido, J., Stark, R., Zecchini, H. I., Rao, R. B., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201386874 · Cited by 65
Pachnis, P., Wu, Z., Faubert, B., Tasdogan, A., Gu, W., Shelton, S. D., Solmonson, A., Rao, A. D., Kaushik, A., Rogers, T. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn9550 · Cited by 65
Labbè, K., LeBon, L., King, B., Vu, N., Stoops, E. H., Ly, N., Lefebvre, A. E. Y. T., Seitzer, P., Krishnan, S., Heo, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52538-5 · Cited by 62
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M. H., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 67
Wu, W., Sun, H.-W., Chen, J., Ouyang, H., Yu, X.-J., Chen, H., Shuang, Z., Shi, M., Wang, Z., & Zheng, L. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0902 · Cited by 63
Control of the Antitumor Immune Response by Cancer Metabolism
Domblides, C., Lartigue, L., & Faustin, B. (2019) · Cells · doi:10.3390/cells8020104 · Cited by 64
Role of Mitochondrial Stress Response in Cancer Progression
Lee, Y. G., Park, D. H., & Chae, Y. C. (2022) · Cells · doi:10.3390/cells11050771 · Cited by 67
Baran, N., Lodi, A., Dhungana, Y., Herbrich, S. M., Collins, M., Sweeney, S., Pandey, R., Skwarska, A., Patel, S., Tremblay, M. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30396-3 · Cited by 64
Self-citationIcard, P., Simula, L., Fournel, L., Leroy, K., Mansuet‐Lupo, A., Damotte, D., Charpentier, M.-C., Durdux, C., Loi, M., Schussler, O., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100852 · Cited by 63
Kuna, R. S., Kumar, A., Gálvez, H., Wessendorf-Rodriguez, K. A., Green, C. R., McGregor, G. H., Cordes, T., Shaw, R. J., Svensson, R. U., & Metallo, C. M. (2023) · Science Advances · doi:10.1126/sciadv.adf0138 · Cited by 63
Self-citationCytosolic reducing power preserves glutamate in retina
Du, J., Cleghorn, W. M., Contreras, L., Linton, J. D., Chan, G. C. ‐., Chertov, A. O., Saheki, T., Govindaraju, V., Sadı́lek, M., Satrústegui, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311193110 · Cited by 62
Metabolic changes in cancer cells upon suppression of MYC
Ansó, E., Mullen, A. R., Felsher, D. W., Matés, J. M., DeBerardinis, R. J., & Chandel, N. S. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-7 · Cited by 64
Targeting metabolism in breast cancer: How far we can go?
Long, J. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.122 · Cited by 65
A key role for transketolase-like 1 in tumor metabolic reprogramming
Díaz‐Moralli, S., Aguilar, E., Marín, S., Coy, J. F., Dewerchin, M. A., Antoniewicz, M. R., Meca‐Cortés, Ó., Notebaert, L., Ghesquière, B., Eelen, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10429 · Cited by 62
Rinaldi, G., Rossi, M., & Fendt, S. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1397 · Cited by 65
Regulation of fatty acid synthesis in immune cells
Qian, X., Yang, Z., Mao, E., & Chen, E. (2018) · Scandinavian Journal of Immunology · doi:10.1111/sji.12713 · Cited by 65
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 63
Altemus, M., Goo, L., Little, A. C., Yates, J. A., Cheriyan, H., Wu, Z.-F., & Merajver, S. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220973 · Cited by 63
Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific Manner
Krishnan, K. C., Floyd, R. R., Sabir, S., Jayasekera, D. W., León‐Mimila, P., Jones, A. E., Cortez, A. A., Shravah, V., Péterfy, M., Stiles, L., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.09.004 · Cited by 62
NaCT/SLC13A5 facilitates citrate import and metabolism under nutrient-limited conditions
Kumar, A., Cordes, T., Thalacker‐Mercer, A. E., Pajor, A. M., Murphy, A. N., & Metallo, C. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109701 · Cited by 60
Self-citationVanderperre, B., Herzig, S., Krznar, P., Hörl, M., Ammar, Z., Montessuit, S., Pierredon, S., Zamboni, N., & Martinou, J. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006056 · Cited by 67
Regulation of Stem Cell Fate by ROS-mediated Alteration of Metabolism
Ryu, J. M., Lee, H. J., Jung, Y. H., Lee, K. H., Kim, D. I., Kim, J. Y., Ko, S. H., Choi, G. E., Chai, I. I., Song, E. J., et al. (2015) · International Journal of Stem Cells · doi:10.15283/ijsc.2015.8.1.24 · Cited by 62
Golias, T., Papandreou, I., Sun, R. C., Kumar, B., Brown, N. V., Swanson, B. J., Pai, R. K., Jaitin, D. A., Le, Q., Teknos, T. N., et al. (2016) · Scientific Reports · doi:10.1038/srep31146 · Cited by 67
Ecker, C., Guo, L., Voicu, S., Gil‐de‐Gómez, L., Medvec, A. R., Cortina, L. E., Pajda, J., Andolina, M., Torres-Castillo, M., Donato, J. L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.084 · Cited by 63
Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas
Guan, X., Luo, L., Begum, G., Kohanbash, G., Song, Q., Rao, A., Amankulor, N., Sun, B., Sun, D., & Jia, W. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0923-z · Cited by 62
Metabolic alterations mediated by STAT3 promotes drug persistence in CML
Patel, S. B., Nemkov, T., Stefanoni, D., Benavides, G. A., Bassal, M. A., Crown, B. L., Matkins, V. R., Camacho, V., Kuznetsova, V., Hoang, A. T., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01315-0 · Cited by 56
Nutritional Exchanges Within Tumor Microenvironment: Impact for Cancer Aggressiveness
Comito, G., Ippolito, L., Chiarugi, P., & Cirri, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00396 · Cited by 60
Yamamoto, T., Hayashida, T., Masugi, Y., Oshikawa, K., Hayakawa, N., Itoh, M., Nishime, C., Suzuki, M., Nagayama, A., Kawai, Y., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2266 · Cited by 60
Acetate as a Metabolic and Epigenetic Modifier of Cancer Therapy
Jaworski, D. M., Namboodiri, A. M. A., & Moffett, J. R. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25305 · Cited by 63
Magnetic resonance spectroscopy metabolite profiles predict survival in paediatric brain tumours
Wilson, M., Cummins, C., MacPherson, L. K. R., Sun, Y., Natarajan, K., Grundy, R. G., Arvanitis, T. N., Kauppinen, R. A., & Peet, A. C. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.002 · Cited by 61
De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
Tarrado‐Castellarnau, M., de Atauri, P., Tarragó‐Celada, J., Perarnau, J., Yuneva, M. O., Thomson, T. M., & Cascante, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167321 · Cited by 60
Jakob, C. G., Upadhyay, A. K., Donner, P. L., Nicholl, E., Addo, S. N., Qiu, W., Ling, C., Gopalakrishnan, S. M., Torrent, M., Cepa, S. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00305 · Cited by 62
miR-137 suppresses cell growth in ovarian cancer by targeting AEG-1
Guo, J., Xia, B., Meng, F., & Lou, G. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.052 · Cited by 60
González‐Menéndez, P., Romano, M., Yan, H., Deshmukh, R. S., Papoin, J., Oburoglu, L., Daumur, M., Dumé, A., Phadke, I., Mongellaz, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108723 · Cited by 60
Overview of Cancer Metabolism and Signaling Transduction
Chae, H., & Hong, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010012 · Cited by 66
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Park, S. J., Yoo, H. C., Ahn, E., Luo, E., Kim, Y., Sung, Y., Yu, Y. C., Kim, K., Min, D. S., Lee, H. S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2045 · Cited by 63
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma
Kroeger, N., Klatte, T., Chamie, K., Rao, P. N., Birkhäuser, F. D., Sonn, G. A., Riss, J., Kabbinavar, F. F., Belldegrun, A. S., & Pantuck, A. J. (2013) · Cancer · doi:10.1002/cncr.27947 · Cited by 63
Metabolic reprogramming: a hallmark of viral oncogenesis
Levy, P. L., & Bartosch, B. (2015) · Oncogene · doi:10.1038/onc.2015.479 · Cited by 62
Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122537 · Cited by 61
ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m093740 · Cited by 59
Self-citationInhibitors of lipogenic enzymes as a potential therapy against cancer
Montesdeoca, N., López, M., Ariza, X., Herrero, L., & Makowski, K. (2020) · The FASEB Journal · doi:10.1096/fj.202000705r · Cited by 58
Metabolism and immunity in breast cancer
Zhang, D., Xu, X., & Ye, Q. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0793-6 · Cited by 58
Altea-Manzano, P., Vandekeere, A., Edwards-Hicks, J., Roldan, M., Abraham, E., Lleshi, X., Guerrieri, A. N., Berardi, D., Wills, J., Junior, J. M., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.10.005 · Cited by 57
Ahmed, E. S. A., Mohamed, H. E., & Farrag, M. A. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320221137435 · Cited by 59
Corbet, C., & Féron, O. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000178 · Cited by 61
Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells
Rajagopalan, K. N., Egnatchik, R. A., Calvaruso, M. A., Wasti, A., Padanad, M. S., Boroughs, L. K., Ko, B., Hensley, C. T., Acar, M., Hu, Z., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0134-4 · Cited by 61
Zhou, X., Chen, R., Yu, Z., Li, R., Li, J., Zhao, X., Song, S., Liu, J., & Huang, G. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0331-3 · Cited by 59
Botman, D., Tigchelaar, W., & Noorden, C. J. F. V. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155414549071 · Cited by 58
Mitochondrial pyruvate carrier function and cancer metabolism
Rauckhorst, A. J., & Taylor, E. B. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.05.003 · Cited by 59
Epigenetic silencing of microRNA-137 enhances ASCT2 expression and tumor glutamine metabolism
Dong, J., Xiao, D., Zhao, Z., Ren, P., Li, C., Hu, Y., Shi, J., Su, H., Wang, L., Liu, H., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.59 · Cited by 61
Chassen, S. S., Ferchaud‐Roucher, V., Gupta, M. B., Jansson, T., & Powell, T. L. (2018) · Clinical Science · doi:10.1042/cs20171340 · Cited by 57
Complexity of macrophage metabolism in infection
He, W., Heinz, A., Jahn, D., & Hiller, K. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.01.020 · Cited by 58
Self-citationAsparagine reinforces mTORC1 signaling to boost thermogenesis and glycolysis in adipose tissues
Xu, Y., Shi, T., Cui, X., Yan, L., Wang, Q., Xu, X., Zhao, Q., Xu, X., Tang, Q., Tang, H., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108069 · Cited by 58
Kaushik, A., Tarangelo, A., Boroughs, L. K., Ragavan, M., Zhang, Y., Wu, C., Li, X., Ahumada, K., Chiang, J., Tcheuyap, V. T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abp8293 · Cited by 56
Metabolic dependencies and targets in ovarian cancer
Zhang, Y., Wang, Y., Zhao, G., Oršulić, S., & Matei, D. E. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108413 · Cited by 65
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma
Dunn, G. P., Andronesi, O. C., & Cahill, D. P. (2013) · Neurosurgical FOCUS · doi:10.3171/2012.12.focus12355 · Cited by 59
Navis, A. C., Niclou, S. P., Fack, F., Stieber, D., van Lith, S. A. M., Verrijp, K. N., Wright, A. J., Stauber, J., Tops, B. B. J., Otte‐Höller, I., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-18 · Cited by 61
Mitochondrial metabolism and energy sensing in tumor progression
Iommarini, L., Ghelli, A. M., Gasparre, G., & Porcelli, A. M. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.02.006 · Cited by 58
Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance
Nwosu, Z. C., Piorońska, W., Battello, N., Zimmer, A. D., Dewidar, B., Han, M., Pereira, S., Blagojevic, B., Castven, D., Charlestin, V., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102699 · Cited by 61
Immunometabolism: new insights and lessons from antigen-directed cellular immune responses
Ramalho, R., Rao, M., Zhang, C., Agrati, C., Ippolito, G., Wang, F., Zumla, A. I., & Maeurer, M. J. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00798-w · Cited by 63
Mitochondria orchestrate macrophage effector functions in atherosclerosis
Dumont, A., Lee, M., Barouillet, T., Murphy, A. J., & Yvan‐Charvet, L. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100922 · Cited by 60
Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions
Bargiela, D., Burr, S. P., & Chinnery, P. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.02.002 · Cited by 60
Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy
Chen, C., Wang, Z., & Qin, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935536 · Cited by 62
Identification of purine biosynthesis as an NADH-sensing pathway to mediate energy stress
Yang, R., Yang, C., Ma, L., Zhao, Y., Guo, Z., Niu, J., Chu, Q., Ma, Y., & Li, B. (2022) · Nature Communications · doi:10.1038/s41467-022-34850-0 · Cited by 60
13 C metabolite tracing reveals glutamine and acetate as critical in vivo fuels for CD8 T cells
Ma, E. H., Dahabieh, M. S., DeCamp, L. M., Kaymak, I., Kitchen-Goosen, S. M., Oswald, B. M., Longo, J., Roy, D. G., Verway, M. J., Johnson, R. M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj1431 · Cited by 53
Dynamic single-cell metabolomics reveals cell-cell interaction between tumor cells and macrophages
Zhang, Y., Shi, M., Li, M., Qin, S., Miao, D., & Bai, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-59878-w · Cited by 60
NADH reductive stress drives metabolic reprogramming
Yang, R., Guo, Z., & Li, B. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.07.005 · Cited by 61
Inhibition of ATP Citrate Lyase Induces an Anticancer Effect via Reactive Oxygen Species
Migita, T., Okabe, S., Ikeda, K., Igarashi, S., Sugawara, S., Tomida, A., Taguchi, R., Soga, T., & Seimiya, H. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.048 · Cited by 58
Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment
Howie, D., Waldmann, H., & Cobbold, S. P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00409 · Cited by 62
Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors
Zhang, X., Milito, A. D., Olofsson, A. M., Gullbo, J., D’Arcy, P., & Linder, S. T. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126020 · Cited by 56
Glioblastoma Stem Cells as a New Therapeutic Target for Glioblastoma
Kalkan, R. (2015) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s30271 · Cited by 57
Metabolic reprogramming as a feast for virus replication
Polčicová, K., Baďurová, L., & Tomášková, J. (2020) · Acta Virologica · doi:10.4149/av_2020_210 · Cited by 57
Glutamine metabolism in Th17/Treg cell fate: applications in Th17 cell-associated diseases
Yang, G., Xia, Y., & Ren, W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1703-2 · Cited by 55
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Hvinden, I. C., Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100469 · Cited by 63
Metabolomics of Breast Cancer: A Review
Subramani, R., Poudel, S., Smith, K. D., Estrada, A., & Lakshmanaswamy, R. (2022) · Metabolites · doi:10.3390/metabo12070643 · Cited by 59
Breathless cancer cells get fat on glutamine
Anastasiou, D., & Cantley, L. C. (2012) · Cell Research · doi:10.1038/cr.2012.5 · Cited by 56
Application of Metabolomics in Thyroid Cancer Research
Wojakowska, A., Chekan, M., Widłak, P., & Pietrowska, M. (2015) · International Journal of Endocrinology · doi:10.1155/2015/258763 · Cited by 58
Hitchler, M. J., & Domann, F. E. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.028 · Cited by 56
Changing appetites: the adaptive advantages of fuel choice
Stanley, I. A., Ribeiro, S. M., Giménez-Cassina, A., Norberg, E., & Danial, N. N. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.010 · Cited by 57
Formation of Renal Cysts and Tumors in Vhl/Trp53 -Deficient Mice Requires HIF1α and HIF2α
Schönenberger, D., Harlander, S., Rajski, M., Jacobs, R. A., Lundby, A., Adlesic, M., Hejhal, T., Wild, P. J., Lundby, C., & Frew, I. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1859 · Cited by 58
Metabolic scavenging by cancer cells: when the going gets tough, the tough keep eating
Michalopoulou, E., Bulusu, V., & Kamphorst, J. J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.256 · Cited by 59
Inhibiting both proline biosynthesis and lipogenesis synergistically suppresses tumor growth
Liu, M., Wang, Y., Yang, C., Ruan, Y., Bai, C., Chu, Q., Cui, Y., Chen, C., Ying, G., & Li, B. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191226 · Cited by 57
Dessai, A. S., Domínguez, M. P., Chen, U.-I., Hasper, J., Prechtl, C., Yu, C. R., Katsuta, E., Dai, T., Zhu, B., Jung, S. Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1708 · Cited by 59
Proliferating tumor cells mimick glucose metabolism of mature human erythrocytes
Ghashghaeinia, M., Köberle, M., Mrowietz, U., & Bernhardt, I. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1618125 · Cited by 55
Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy
Sanctis, F. D., Adamo, A., Canè, S., & Ugel, S. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00965-1 · Cited by 54
Metabolic circuits in neural stem cells
Kim, D., Rhee, I., & Paik, J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1686-0 · Cited by 59
13C Isotope-Assisted Methods for Quantifying Glutamine Metabolism in Cancer Cells
Zhang, J., Ahn, W. S., Gameiro, P. A., Keibler, M. A., Zhang, Z., & Stephanopoulos, G. N. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416618-9.00019-4 · Cited by 55
Self-citationMicroRNA in Metabolic Re-Programming and Their Role in Tumorigenesis
Tomasetti, M., Amati, M., Santarelli, L., & Neužil, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050754 · Cited by 57
LKB1 promotes metabolic flexibility in response to energy stress
Parker, S. J., Svensson, R. U., Divakaruni, A. S., Lefebvre, A. E. Y. T., Murphy, A. N., Shaw, R. J., & Metallo, C. M. (2016) · Metabolic Engineering · doi:10.1016/j.ymben.2016.12.010 · Cited by 54
Self-citationMass Spectrometry Imaging in Oncology Drug Discovery
Goodwin, R. J. A., Bunch, J., & McGinnity, D. F. (2017) · Advances in cancer research · doi:10.1016/bs.acr.2016.11.005 · Cited by 58
Computational Strategies for a System-Level Understanding of Metabolism
Cazzaniga, P., Damiani, C., Besozzi, D., Colombo, R., Nobile, M. S., Gaglio, D., Pescini, D., Molinari, S., Mauri, G., Alberghina, L., et al. (2014) · Metabolites · doi:10.3390/metabo4041034 · Cited by 56
Role of Reductive versus Oxidative Stress in Tumor Progression and Anticancer Drug Resistance
Chun, K., Kim, D., & Surh, Y. (2021) · Cells · doi:10.3390/cells10040758 · Cited by 56
Inaccurate quantitation of palmitate in metabolomics and isotope tracer studies due to plastics
Yao, C.-H., Liu, G., Yang, K., Gross, R. W., & Patti, G. J. (2016) · Metabolomics · doi:10.1007/s11306-016-1081-y · Cited by 53
Lane, A. N., Tan, J. D., Wang, Y., Yan, J., Higashi, R. M., & Fan, T. W. ‐. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.01.010 · Cited by 55
Farrugia, M. A., & Puglielli, L. (2018) · Journal of Cell Science · doi:10.1242/jcs.221747 · Cited by 52
Sánchez‐González, C., Nuevo‐Tapioles, C., Martín, J. C. H., Pereira, M. P., Sanz, S. S., de Molina, A. R., Cuezva, J. M., & Formentini, L. (2020) · The EMBO Journal · doi:10.15252/embj.2019103812 · Cited by 55
Liu, Y., Duan, C., Dai, R., & Zeng, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.739392 · Cited by 58
Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells
Samuel, S. M., Varghese, E., Koklesová, L., Líšková, A., Kubatka, P., & Büsselberg, D. (2020) · Cancers · doi:10.3390/cancers12092482 · Cited by 58
Expanding Roles of De Novo Lipogenesis in Breast Cancer
Simeone, P., Tacconi, S., Longo, S., Lanuti, P., Bravaccini, S., Pirini, F., Ravaioli, S., Dini, L., & Giudetti, A. M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18073575 · Cited by 55
Lipid Catabolism and ROS in Cancer: A Bidirectional Liaison
Castelli, S., Falco, P. D., Ciccarone, F., Desideri, E., & Ciriolo, M. R. (2021) · Cancers · doi:10.3390/cancers13215484 · Cited by 57
Metadata
- Authors
- Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., Kelleher, J. K., Vander Heiden, M. G., Iliopoulos, O., & Stephanopoulos, G.
- Affiliations
- Massachusetts Institute of Technology (US)
- Massachusetts General Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Iliopoulos, Othon
- Stephanopoulos, Gregory
- ORCID
- Venue
- Nature
- Published
- 2011-11-20
- Volume
- 481
- Issue
- 7381
- Pages
- 380-384
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3710581
- OpenAlex
- W2116516144
- Cited by
- 1,791
- References
- 43
- Citations by year
- 2026: 82 · 2025: 95 · 2024: 96 · 2023: 137 · 2022: 156 · 2021: 143 · 2020: 149 · 2019: 125 · 2018: 100 · 2017: 135 · 2016: 129 · 2015: 125 · 2014: 119 · 2013: 112 · 2012: 84
- FWCI
- 34.61
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- RePEc: Research Papers in Economics (submittedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Damon Runyon Cancer Research Foundation
- Wellcome Trust
- Agios Pharmaceuticals
- National Institutes of Health
- National Cancer Institute (R01CA160458, R01CA122591, P30CA014051)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK075850)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- IDH1, lipogenesis, hypoxia, reductive carboxylation, alpha-ketoglutarate, acetyl-CoA, fatty acid synthesis, VHL, renal cell carcinoma, cancer metabolism, mitochondrial dysfunction, aerobic glycolysis
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Acetyl Coenzyme A, Carbon, Carcinoma, Renal Cell, Cells, Cultured, Citric Acid Cycle, Glutamine, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Kidney Neoplasms, Oxidation-Reduction, Oxygen, Cell Hypoxia, CD8-Positive T-Lymphocytes, Palmitic Acid, Cell Line, Tumor, Lipogenesis, Aryl Hydrocarbon Receptor Nuclear Translocator, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
